Wall Street brokerages expect Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) to post earnings per share (EPS) of ($0.02) for the current fiscal quarter, according to Zacks. Three analysts have made estimates for Vanda Pharmaceuticals’ earnings, with the highest EPS estimate coming in at $0.01 and the lowest estimate coming in at ($0.06). Vanda Pharmaceuticals posted earnings per share of ($0.04) during the same quarter last year, which would indicate a positive year-over-year growth rate of 50%. The company is scheduled to announce its next quarterly earnings results on Wednesday, February 13th.
According to Zacks, analysts expect that Vanda Pharmaceuticals will report full-year earnings of $0.22 per share for the current financial year, with EPS estimates ranging from $0.18 to $0.28. For the next financial year, analysts expect that the company will post earnings of $0.66 per share, with EPS estimates ranging from $0.23 to $0.99. Zacks’ EPS calculations are a mean average based on a survey of analysts that follow Vanda Pharmaceuticals.
Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings results on Wednesday, November 7th. The biopharmaceutical company reported $0.13 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.05) by $0.18. Vanda Pharmaceuticals had a net margin of 0.73% and a return on equity of 0.68%. The business had revenue of $49.13 million during the quarter, compared to analysts’ expectations of $49.44 million. During the same quarter in the prior year, the company posted ($0.03) EPS. The firm’s revenue for the quarter was up 18.9% compared to the same quarter last year.
Large investors have recently bought and sold shares of the company. Trexquant Investment LP purchased a new position in Vanda Pharmaceuticals during the 2nd quarter valued at about $212,000. Hartford Investment Management Co. purchased a new position in Vanda Pharmaceuticals during the 2nd quarter valued at about $214,000. NumerixS Investment Technologies Inc lifted its position in Vanda Pharmaceuticals by 92.9% during the 2nd quarter. NumerixS Investment Technologies Inc now owns 11,835 shares of the biopharmaceutical company’s stock valued at $227,000 after acquiring an additional 5,700 shares during the period. Xact Kapitalforvaltning AB purchased a new position in Vanda Pharmaceuticals during the 2nd quarter valued at about $240,000. Finally, Meeder Asset Management Inc. lifted its position in Vanda Pharmaceuticals by 164.6% during the 3rd quarter. Meeder Asset Management Inc. now owns 11,417 shares of the biopharmaceutical company’s stock valued at $261,000 after acquiring an additional 7,102 shares during the period. 93.92% of the stock is owned by hedge funds and other institutional investors.
Shares of NASDAQ:VNDA traded up $3.01 on Thursday, hitting $23.46. The company had a trading volume of 1,937,092 shares, compared to its average volume of 689,271. Vanda Pharmaceuticals has a 1 year low of $11.90 and a 1 year high of $25.07. The stock has a market cap of $1.05 billion, a price-to-earnings ratio of -67.03 and a beta of 1.06.
About Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.
Read More: Short Selling Stocks and Day Traders
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.